Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus

Watts, Nelson B., Bilezikian, John P., Usiskin, Keith, Edwards, Robert, Desai, Mehul, Law, Gordon, Meininger, Gary·2016·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2015-3167

Cited by (452)

Items 301–400 of 452

  1. Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visión adipocéntrica del abordaje de la diabetes
    Juan José Gorgojo Martínez · 2016 · Medicina Clínica
  2. Diabetes and Bone Involvement in Primary Hyperparathyroidism: Literature Review and Our Personal Experience
    Elena Castellano, Roberto Attanasio, Alberto Boriano, Valentina Borretta, Francesco Tassone, Giorgio Borretta · 2021 · Frontiers in Endocrinology
  3. Relationship of Bone Turnover Markers with Serum Uric Acid-to-Creatinine Ratio in Men and Postmenopausal Women with Type 2 Diabetes
    Yuling Xing, Jing Liu, Huanxin Liu, Huijuan Ma · 2022 · Diabetes Metabolic Syndrome and Obesity
  4. Evaluation of the Association between Low-Density Lipoprotein (LDL) and All-Cause Mortality in Geriatric Patients with Hip Fractures: A Prospective Cohort Study of 339 Patients
    Xin Kang, Bin Tian, Zandong Zhao, Bin-Fei Zhang, Ming Zhang · 2023 · Journal of Personalized Medicine
  5. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH
    Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch, May E. Montasser, Amber L. Beitelshees, Simeon I. Taylor · 2023 · The Journal of Clinical Endocrinology & Metabolism
  6. In nondiabetic C57BL/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner
    Carolyn Chlebek, Casey McAndrews, Samantha Costa, Victoria DeMambro, Shoshana Yakar, Clifford james Rosen · 2024 · JBMR Plus
  7. Recomendaciones sobre el efecto de los fármacos antidiabéticos en el hueso
    Pedro Rozas-Moreno, Rebeca Reyes‐García, Esteban Jódar-Gimeno, Mariela Varsavsky, Inés Luque-Fernández, María Cortés Berdonces, Manuel Muñoz‐Torres · 2017 · Endocrinología Diabetes y Nutrición
  8. Insulin and Other Hypoglycemic Drugs
    Jasmine M. Pittman, Laura A. Schalliol, Sidhartha D. Ray · 2017 · Side effects of drugs annual
  9. Osteoporosis in diabetes mellitus patients
    Peter Jackuliak, Magdaléna Kovářová, Martin Kužma, Juraj Payer · 2021 · Vnitřní lékařství
  10. Management of Diabetes Mellitus
    Alicia Josephine Jenkins, EMMA S. SCOTT, Jordan Fulcher, Gary Kilov, Andrzej S. Januszewski · 2018 · Contemporary cardiology
  11. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature
    Carlos Hernández-Quiles, Nieves Ramírez‐Duque, Domingo Acosta-Delgado · 2018 · Current Diabetes Reviews
  12. Risk of fracture with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: an updated meta-analysis of randomized controlled trials
    Mahdieh Khoshzaban Banisi · 2025 · International Journal of Physiology Pathophysiology and Pharmacology
  13. Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review
    Ziyang Zhang, Yupeng Li, Harvest Feng Gu, Nan Li · 2025 · Biomedicine & Pharmacotherapy
  14. Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines
    Tamás T. Várkonyi, Krisztina Kupai, Hsu Lin Kang, Danica Matusovits, Dániel Priksz, Ákos Várkonyi, Csaba Lengyel, Anikó Pósa · 2026 · Antioxidants
  15. A Randomized Controlled Trial on the Effect of Luseogliflozin on Bone Microarchitecture Evaluated Using HR-pQCT in Elderly Type 2 Diabetes
    Riyoko Shigeno, Ichiro Horie, Ai Haraguchi, Ryuji Niimi, Ko Chiba, Shigeki Tashiro, Yurika Kawazoe, Shuntaro Sato, Makoto Osaki, Atsushi Kawakami et al. · 2024 · Diabetes Therapy
  16. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies
    Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, Julliane Vasconcelos Joviano‐Santos · 2024 · Chemico-Biological Interactions
  17. Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico, in vitro, and in vivo analysis
    Faraha Ahmed, Syed Sufian Ahmad, Mohammad Mumtaz Alam, Mohammad Shaquiquzzaman, Mohammad Altamish, Anuja Krishnan, Divya Vohora, Abul Kalam Najmi, Mohammad Ahmed Khan · 2024 · Journal of Pharmacy and Pharmacology
  18. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
    Alexander Kühn, Jean Park, Adline Ghazi, Vanita R. Aroda · 2017 · Current Cardiology Reports
  19. Clinical impact of misinterpretation of dual-energy X-ray absorptiometry during the evaluation of osteoporotic patients
    Sonia Cerdas Pérez, L. E. Herrera, E. González · 2021 · Climacteric
  20. Presenting Turkish Inappropriate Medication Use in the Elderly (TIME) Criteria Set in Turkish
    Gülistan Bahat, Birkan İlhan, Tuğba Erdoğan, Meltem Gulhan Halil, Sumru Savaş, Zekeriya Ülger, Filiz Akyüz, Ahmet Kaya Bilge, Sibel Çakır, Kutay Demirkan et al. · 2021 · European Journal of Geriatrics and Gerontology
  21. Administration of Once-daily Canagliflozin to a Non-diabetic Patient in Addition to Standard Aerobic Exercise: A Case Report
    Sayak Roy · 2019 · Cureus
  22. SGLT2 inhibitors: Exploring the effects in humans and horses
    T. Sundra, V. Matthews, P. Harris, D. Rendle · 2024 · Equine Veterinary Education
  23. Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome
    Jiaxin Hua, Qingyuan Wang, Ye Liu, Shengwei Luo, Ao Shi, Zhiwei Yan, Jing Zhang, Wenli Gu, Lihan Zhu, Yuling Zhang et al. · 2026 · Cardiovascular Diabetology
  24. Urological impact of flozins (SGLT2 inhibitors): an EAU Endourology review of risks, side effects and clinical considerations
    Ali Talyshinskii, Carlotta Nedbal, Bhaskar Kumar Somani · 2025 · Current Opinion in Urology
  25. Recommendations on the effect of antidiabetic drugs in bone
    Pedro Rozas-Moreno, Rebeca Reyes‐García, Esteban Jódar-Gimeno, Mariela Varsavsky, Inés Luque-Fernández, María Cortés Berdonces, Manuel Muñoz‐Torres · 2017 · Endocrinología Diabetes y Nutrición (English ed )
  26. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
    Richard E. Pratley, Eugênio Cersósimo · 2017 · Clinical Diabetes
  27. Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozotocin in rats.
    Piotr Londzin, M. Zych, A. Janas, S. Siudak, J. Folwarczna · 2025 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  28. Hip fractures and type 2 diabetes in the elderly: Risk factors analysis of the Nedices cohort
    Federico Hawkins Carranza, Cristina Martín‐Arriscado Arroba, Arturo Corbatón Anchuelo, Guillermo Martínez Diaz‐Guerra, Félix Bermejo Pareja · 2025 · Diabetes & Metabolism
  29. Conséquences osseuses du diabète et de ses traitements
    Bernard Cortet, Stéphanie Lucas, Isabelle Legroux-Gérot, Guillaume Penel, Christophe Chauveau, Julien Paccou · 2018 · Revue du Rhumatisme
  30. Mise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2
    Pierre Gourdy · 2019 · Médecine des Maladies Métaboliques
  31. Axial BMD in Diabetic and Nondiabetic Southeast Asians with HIP Fractures: Do Race and Body Mass Index Matter?
    Manju Chandran, Donovan Tay, Matthew Zhen-Wei Tan, Ying Hao, Xiao Feng Huang, Joan Joo Ching Khoo, Troy Hai Kiat Puar · 2016 · Endocrine Practice
  32. Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors
    Cahit Demirkiran, Şeniz Demiryürek, Abdullah Tuncay Demiryürek · 2024 · Mini-Reviews in Medicinal Chemistry
  33. Impact of SGLT2i on bone health in patients with lupus nephritis: randomized double blinded placebo-controlled clinical trial
    Mohamed Hosney Badawi, Eman Nagy, Ehab Wahba Wafa, Amr A El-Husseini, Nourelsabah Mohamed, Mohamed Abou El‐Ghar, Wael Ibrahim Mortada, Kareem A. Nabieh, Mohamed Abdel kader Sobh · 2025 · Journal of Nephrology
  34. Bone Health in Type 1 and Type 2 Diabetes: Pathophysiological Mechanisms, Clinical Implications, and Management Strategies
    Hermine Carine Pouabe Epse Bodah, Suraiya Rahman Shifa, Sara Saleh, Tuba Abeer Hashmi, Tuleen Al Shawa, Badreshiya Kajal Akshaykumar, Nabeel Sufwan, Rajvinder Kaur, Andrii Shevchuk, Usman Haq et al. · 2025 · SN Comprehensive Clinical Medicine
  35. Underlying Mechanisms of Osteoporosis in the Context of Multimorbidity: Clinical Challenges and Management Strategies
    Alberto Castagna, Carmelo Pujia, Elisa Mazza, Samantha Maurotti, Yvelise Ferro, Valeria Rizzo, Martina Formica, Rosy Conforto, Caterina Mercuri, Angela Sciacqua et al. · 2026 · Nutrients
  36. Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2)
    Lauter Eston Pelepenko, Machado dos Reis Luciene, Luzia Naôko Shinohara Furukawa, Rodrigo Bueno de Oliveira · 2026 · Calcified Tissue International
  37. Effects of gliflozins on bone health of patients with chronic kidney disease: a systematic review
    Mariana Cassani de Oliveira, Lorena Rufino, Ana Laura Mendes Lourenço, Eric Aragão Corrêa, Fabrice Mac‐Way, Lauter Eston Pelepenko, Niels Olsen Saraiva Câmara, Rodrigo Bueno de Oliveira · 2026 · Journal of Nephrology
  38. The CANVAS trial programme raises more questions than answers
    Miles Fisher · 2017 · Practical Diabetes
  39. Uso de fármacos para la osteoporosis en pacientes con diabetes mellitus tipo 2: estudio de cohortes de base poblacional
    Daniel Martínez-Laguna, Carlen Reyes, Cristina Carbonell-Abella, Eladio Losada, Berta Soldevila, Dı́dac Mauricio, Adolfo Díez‐Pérez, Xavier Nogués, Daniel Prieto‐Alhambra · 2017 · Revista de Osteoporosis y Metabolismo Mineral
  40. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
    Ameena Madan Paramasivan, Archana Purushothaman, Cyrus V Desouza · 2018 · Current Diabetes Reports
  41. WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
    Oren Steen, Ronald Goldenberg · 2017 · Canadian Journal of Diabetes · Retracted
  42. Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
    Irina Vladimirovna Glinkina, Балашова Анастасия Владимировна, A. S. Shyman, A. V. Oderiy, S. A. Khan, Рунова Гюзель Евгеньевна, Т. Б. Моргунова, Valentin V. Fadeev · 2021 · Meditsinskiy sovet = Medical Council
  43. Age- and obesity-related metabolic changes and their impact on the incidence of digestion, metabolism, and immune health
    Małgorzata Bukowiecka‐Matusiak, Izabela Burzyńska-Pędziwiatr, Lucyna A. Woźniak · 2022 · Elsevier eBooks
  44. In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
    Abhijit Debnath, Shalini Sharma, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Ankit Kumar, Arpita Dua, Priya Singhal, Arvind Kumar, Gurvinder Singh · 2023 · Current Drug Discovery Technologies
  45. Bibliometric and visualized analysis of type 2 diabetic osteoporosis from 2013 to 2022
    Siyu Chen, Jing Liao, Peixin Huang, Kefeng Wu, Lu-Ming Deng · 2024 · Archives of Osteoporosis
  46. SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
    Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar · 2024 · Expert Opinion on Therapeutic Patents
  47. Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond
    Pratikeswar Panda, Rajaram Mohapatra, Biswajit Samantaray · 2024 · Current Drug Research Reviews
  48. Recent Advances in Promoting Bone Regeneration in Type 2 Diabetes Using Drug Delivery Vehicles and Vehicle‐Free Therapeutics
    Yasamin Pesaran Afsharian, Mostafa Rahimnejad, Sayed Mahmood Rabiee, Farideh Feizi, Hermann Seitz · 2025 · Advanced Therapeutics
  49. Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors
    Sumanth KHAKDE, Hafsa Jawaid, Farah Yasmin, Mashal Binte Ali, Abdur REHMAN · 2022 · Minerva Endocrinology
  50. Evaluation of Usage of a Fracture Risk Assessment by FRAX Tool in Adults With Type 2 Diabetes Mellitus
    Sílvia Santos Monteiro, Tiago Santos, Liliana Fonseca, Jorge M. Dores · 2023 · Cureus
  51. Bolstering your armamentarium with SGLT2 inhibitors
    Lucia M. Novak, Davida F. Kruger · 2017 · The Nurse Practitioner
  52. L’internista ospedaliero nella gestione del paziente diabetico complesso
    Guest Editors L. Magnani, Giampietro Beltramello, D. Brancato, Andrea Fontanella, Roberto Nardi · 2018 · Italian Journal of Medicine
  53. Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes
    Priti Meena, Vinant Bhargava, Anil Kumar Bhalla, Devinder Singh Rana, Alok Kumar Mantri · 2021 · Postgraduate Medical Journal
  54. Diabetes, diabetic medications, and risk of fracture
    Luca D’Onofrio, Andrea Palermo, Nicola Napoli · 2020 · Elsevier eBooks
  55. Bone metabolism in diabetes mellitus: focus on vitamin K2
    Радугин Федор Михайлович, Т. Л. Каронова · 2022 · Osteoporosis and Bone Diseases
  56. Aspects of the safety of hypoglycemic drugs according to the results of clinical trials
    А. Л. Хохлов, Горелов Кирилл Витальевич, Ju. V. Rybachkova · 2023 · Patient-Oriented Medicine and Pharmacy
  57. The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes
    Kathryn Snyder, Katherine E. Griffin, Amber J. Hackstadt, Amir Javid, Adriana M. Hung, Robert A. Greevy, Christianne L. Roumie · 2025 · American Journal of Medicine Open
  58. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever
    Jan Basile · 2016 · Hospital Practice
  59. Insulin Other Hypoglycemic Drugs
    Sara N. Trovinger, Sandra L. Hrometz, Sipan Keshishyan, Sidhartha D. Ray · 2016 · Side effects of drugs annual
  60. Antidiabetic drugs and their effect on bone
    Peter Jackuliak, Martin Kužma, Juraj Payer · 2017 · Vnitřní lékařství
  61. Research Progress on the Relationship between Sarcopenia and Osteoporosis in Type 2 Diabetes Mellitus
    金霞 李 · 2021 · Advances in Clinical Medicine
  62. OSTEOCALCIN ROLE IN THE REGULATION OF INSULIN SECRETION AND OSTEOTROPIC EFFECTS OF DIFFERENT CLASSES OF ANTI-DIABETIC DRUGS (LITERATURE REVIEW AND OWN RESEARCH)
    Алла Ковальчук, Олеся Зінич, О.В. Prybyla, N.M. Кushnareva, В. М. Ковальчук, К.О. Shyshkan-Shyshova · 2022 · World Science
  63. Knowledge and practice of community pharmacists towards SGLT2 inhibitors
    Abdelrahim M. Alqudah, Muna K. Oqal, Ahmed Mohammad Al‐Smadi, Esam Y. Qnais, Mohammed Ali Wedyan, Majd Abu Gneam, Roaa Alnajjar, Manar Alajarmeh, Elaf Yousef, Omar Gammoh · 2022 · F1000Research
  64. Knowledge and practice of community pharmacists towards SGLT2 inhibitors
    Abdelrahim M. Alqudah, Muna K. Oqal, Ahmed Mohammad Al‐Smadi, Esam Y. Qnais, Mohammed Ali Wedyan, Majd Abu Gneam, Roaa Alnajjar, Manar Alajarmeh, Elaf Yousef, Omar Gammoh · 2022 · F1000Research
  65. Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause
    Н. В. Тимкина, N. Yu. Semenova, А. В. Симаненкова, Vsevolod Alexandrovich Zinserling, Timur Dmitrievich Vlasov, А. А. Байрамов, Хальзова Александра Константиновна, Anzhelika Shimshilashvili, В. А. Тимофеева, Т. Л. Каронова · 2023 · Diabetes Mellitus
  66. Bone remodeling in experimental diabetes mellitus and surgical menopause in Wistar rats
    N. V. Timkina, A. Simanenkova, A. Bayramov, M. A. Kokina, N. Semenova, A. Z. Gagiev, T. Karonova, E. N. Grineva · 2023 · Obesity and Metabolism
  67. Sodium Glucose Cotransporter-2 Inhibitors: An Overview from Evolution to Clinical Implications
    Ramya Ravi, Viswanathan Balasubramaniam, Sameer Dhingra, Krishna Murti, Sivasankaran Ponnusankar · 2024 · Indian Journal of Pharmaceutical Sciences
  68. Osteoporose und Typ-2-Diabetes
    A. Egger, MARIUS E. KRAENZLIN, Christian Meier · 2016 · Der Diabetologe
  69. EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
    Rishad Ahmed, Pallavi Kawatra · 2017 · BLDE University Journal of Health Sciences
  70. Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia
    Д. А. Лебедев, Alina Yu. Babenko · 2018 · Meditsinskiy sovet = Medical Council
  71. Diabetes and bone
    Caterina Conte, Roger Bouillon, Nicola Napoli · 2019 · Elsevier eBooks
  72. Diabetes és a csontrendszer
    Peter L. Lakatos, Zsuzsanna Putz · 2017 · Diabetologia Hungarica
  73. Profil de tolérance des inhibiteurs de SGLT2 : le point en 2020
    Patrice Darmon · 2020 · Médecine des Maladies Métaboliques
  74. Impact of glucose-lowering medications on bone health in diabetes
    Palak U. Choksi, MengHee Tan · 2020 · Elsevier eBooks
  75. Diabetes mellitus: How being too sweet leads to skeletal fragility
    Rodrigo J. Valderrábano · 2020 · Elsevier eBooks
  76. The combined impact of diabetes mellitus and chronic kidney disease on mineral metabolism and bone fragility
    Sandra Cooke-Hubley, Christopher S. Kovács · 2020 · Elsevier eBooks
  77. Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease
    Eudora Eng, Susan E. Quaggin · 2022 · Springer eBooks
  78. Effects on the skeleton from medications used to treat nonskeletal disorders
    Nelson B. Watts · 2020 · Elsevier eBooks
  79. Safety of SGLT2 Inhibitors in CKD
    Mirela A. Dobre · 2022 · Clinical Journal of the American Society of Nephrology
  80. SGLT2 inhibitors and bone health in CKD
    Mathias Loberg Haarhaus · 2026 · Clinical Kidney Journal
  81. [Diagnosis and management of patients with diabetes and co-existing osteoporosis (Update 2023) : Common guideline of the Austrian Society for Bone and Mineral Research and the Austrian Diabetes Society].
    Christian Muschitz, Alexandra Kautzky-Willer, Yvonne Winhofer, Martina Rauner, Judith Haschka, Daniel Cejka, Robert Wakolbinger-Habel, Peter Pietschmann · 2023 · PubMed Central
  82. Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk
    Aris Liakos, Eleni Bekiari, Απόστολος Τσάπας · 2016 · Current Cardiovascular Risk Reports
  83. Resúmenes de las Conferencias Diabetes, Obesidad y Lípidos
    Asociación Colombiana de Endocrinología Diabetes y Metabolismo · 2017 · Revista Colombiana de Endocrinología Diabetes & Metabolismo
  84. Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment
    Aşkın Güngüneş, İrfan Karahan, Çağar Alp · 2017 · Ortadoğu Tıp Dergisi
  85. The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review
    Hyung Woo Lee, Sun Joon Moon, Hee Sim Han, Eun Jeong Shin, Jin Hee Baek, Hyun-Joo Han, Young Min Cho, Kwi Suk Kim · 2017 · Journal of Korean Diabetes
  86. Einfluss oraler Antidiabetika auf Knochenstoffwechsel und Frakturrisiko
    Cyril Traechslin, Janina Vavanikunnel, MARIUS E. KRAENZLIN, Christian Meier · 2018 · Osteologie/Osteology
  87. Bone and Diabetes
    A. Palermo, A. Naciu, G. Tabacco, L. D'Onofrio, N. Napoli · 2018 · Springer eBooks
  88. Diabetes and Fracture Risk
    Serge Ferrari, Nicola Napoli, Ann V. Schwartz · 2018 · Primer on the metabolic bone diseases and disorders of mineral metabolism
  89. Effects on the Skeleton from Medications Used to Treat Nonskeletal Disorders
    Nelson B. Watts · 2018 · Wiley eBooks
  90. RISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    G. M. NURULLINA, Ахмадуллина Гузяль Илгисовна, O. V. Krasnoperova, M. M. Alekseeva, O. V. ALEKSANDROVA, A. V. CHERNOVA · 2018 · Кубанский научный медицинский вестник
  91. Fall 51: Therapie – 72 Jahre, ♀, DM Typ 2, Osteoporose, SGLT-2-Inhibitoren
    Chrisitan Kasperk · 2018 · Springer eBooks
  92. Diabetic Pharmacotherapies in Kidney Disease
    Deborah A. Chon, Rachael T. Oxman, RASHMI S. MULLUR, Jane Eileen Weinreb · 2019 · Springer eBooks
  93. Sodium Glucose Cotransporter-2 Inhibition and Renal Function
    Harindra Rajasekeran · 2018 · TSpace (University of Toronto)
  94. Falls and Fall-Risk-Increasing Drugs (FRIDs)
    Sydney P. Springer, Megan Carr · 2017 · The American Pharmacists Association eBooks
  95. Current status of Sodium-Glucose Co-Transporter Type 2 (SGLT2) inhibitors in treating diabetes mellitus
    Vijay Motiram Motghare, Ingale Nikita S, Turankar Avinash V, Wagh Mitali S · 2021 · Indian Journal of Pharmacy and Pharmacology
  96. Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
    Zay Myo Htet, Mahzuz Karim · 2021 · Journal of the Royal Society of Medicine
  97. From Ptolemy to Copernicus: a new proposal for the care of diabetes
    Maria Chantal Ponziani · 2019 · The Journal of AMD
  98. Osteoporose bei Diabetes mellitus
    Elena A. Tsourdi, Lorenz Christian Hofbauer · 2021 · Diabetes aktuell
  99. Rhizoma Drynariae protects against Canaglifloxacin induced bone loss
    Ali Alqahtani, Khalid A. Asseri, Yahya I. Asiri, Krishnaraju Venkatesan, Noohu Abdulla Khan, Sirajudeen Shaik Alavudeen, Ester Mary Pappiya, Directorate of General Health Affair, Ministry of Health, Najran, KSA, Premalatha Paulsamy, R. Natarajan et al. · 2021 · International Journal of Current Research in Chemistry and Pharmaceutical Sciences
  100. Adverse effect of Canaglifloxacin on bone is reversed by Puerariae radix in rat model of diabetics
    Yahya I. Asiri, Ali Alqahtani, Khalid A. Asseri, Krishnaraju Venkatesan, Noohu Abdulla Khan, Vigneshwaran Easwaran, Ester Mary Pappiya, Directorate of General Health Affair, Ministry of Health, Najran, KSA, Premalatha Paulsamy, R. Natarajan et al. · 2021 · International Journal of Current Research in Chemistry and Pharmaceutical Sciences